Cero Therapeutics Holdings, Inc.

Name: Cero Therapeutics Holdings, Inc. standardized financial statements, quarterly
Creator: Listed

CEROOTCCIK 1870404HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$3.8m, Q2 FY2026

Net income−$1.0m, Q2 FY2026

Cero Therapeutics Holdings, Inc., income statement, quarterly
Line item	Unit	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q2 FY20252024-06-30	Q3 FY20252024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Research and development	$k	1,800	1,193	1,278	1,018	2,714	1,774	2,908	2,754	2,386	not reported	2,338	1,736
Operating income	$k	(2,438)	(2,414)	(1,536)	(1,121)	(5,148)	(4,402)	(4,951)	(4,724)	(4,363)	not reported	(4,846)	(3,846)
Interest expense	$k	(0.0)	(59.4)	(0.2)	(20.1)	17.0	(4.4)	not reported	not reported	not reported	not reported	166	690
Income tax	$k	not reported	44.7	25.8	24.4	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$k	(2,438)	(2,093)	(1,349)	(1,265)	(2,449)	(4,228)	(5,106)	(5,417)	(4,856)	(4,541)	(5,886)	(1,029)
Diluted EPS	$ per share	(0.27)	(0.23)	(0.15)	not reported	(302.32)	(170.22)	(31.82)	(61.71)	(9.10)	not reported	(0.20)	(0.70)
Basic EPS	$ per share	(0.27)	(0.23)	(0.15)	not reported	(302.32)	(170.22)	(31.82)	(61.71)	(9.10)	not reported	(0.20)	(0.70)

Balance sheet

Cash and equivalents$862.8k, Q2 FY2026

Long-term debt$136.8k, Q1 FY2026

Shareholders' equity−$30.5m, Q2 FY2026

Cero Therapeutics Holdings, Inc., balance sheet, quarterly
Line item	Unit	FY20232023-12-31	period not labelled2024-02-14	Q1 FY20252024-03-31	Q2 FY20252024-06-30	Q3 FY20252024-09-30	FY20252024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$bn	0.0	not reported	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	857	0.0
Current assets	$bn	0.0	not reported	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total assets	$bn	0.0	not reported	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Current liabilities	$bn	0.0	not reported	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total liabilities	$bn	0.0	not reported	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-term debt	$bn	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	0.0	not reported
Shareholders' equity	$bn	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)

Cash flow

Operating cash flow−$7.9m, Q2 FY2026

Share repurchases$27.8m, Q4 FY2023

Cero Therapeutics Holdings, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q4 FY20222022-12-31	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	(0.2)	(0.4)	(0.2)	(0.9)	(0.3)	(0.2)	not reported	not reported	not reported	not reported	2.8	(7.9)
Dividends paid	$m	not reported	not reported	not reported	not reported	not reported	not reported	0.1	0.0	0.0	0.0	0.1	not reported
Share repurchases	$m	not reported	not reported	not reported	not reported	not reported	27.8	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)42.18m, Q2 FY2026

Cero Therapeutics Holdings, Inc., shares, quarterly
Line item	Unit	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q2 FY20252024-06-30	Q3 FY20252024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	9.1	9.1	9.1	0.0	0.0	0.2	0.5	1.3	28.8	42.2

Shares outstanding: 71.63m at Aug 13, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. Listed shows no prices and gives no investment advice.